Moderna (MRNA) Competitors

argenx (NASDAQ:ARGX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Is ARGX or MRNA more profitable?

argenx has a net margin of -2.11% compared to Moderna's net margin of -110.04%. argenx's return on equity of -1.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Moderna	-110.04%	-28.74%	-21.83%

Does the MarketBeat Community prefer ARGX or MRNA?

argenx received 441 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.35% of users gave argenx an outperform vote while only 53.75% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 656 67.35%	Underperform Votes 318 32.65%
Moderna	Outperform Votes 215 53.75%	Underperform Votes 185 46.25%

Does the media prefer ARGX or MRNA?

In the previous week, argenx had 3 more articles in the media than Moderna. MarketBeat recorded 31 mentions for argenx and 28 mentions for Moderna. Moderna's average media sentiment score of 0.98 beat argenx's score of 0.97 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	14 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in ARGX or MRNA?

60.3% of argenx shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 2.4% of argenx shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation & earnings, ARGX or MRNA?

argenx has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.19B	16.12	-$295.05M	$12.59	46.14
Moderna	$3.20B	3.17	-$3.56B	-$9.28	-2.82

Do analysts rate ARGX or MRNA?

argenx presently has a consensus target price of $690.33, suggesting a potential upside of 18.83%. Moderna has a consensus target price of $58.70, suggesting a potential upside of 124.05%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has more risk and volatility, ARGX or MRNA?

argenx has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Moderna has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

Summary

argenx beats Moderna on 11 of the 18 factors compared between the two stocks.